stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Total debt
Mirum Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $309.8M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $731.3M. Over the past ten years it has ranged from $3.3M (fiscal 2019) to $309.8M (fiscal 2025) — the current reading is the highest in ten years. Mirum Pharmaceuticals, Inc. ranks 21st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $309.8M | 0.56% |
| FY2024 | $308.1M | 0.54% |
| FY2023 | $306.4M | 116.39% |
| FY2022 | $141.6M | 7.42% |
| FY2021 | $131.8M | 162.19% |
| FY2020 | $50.3M | 1,446.54% |
| FY2019 | $3.3M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $731.3M | (2.51%) |
| Jun 2026 | $750.1M | 141.77% |
| Mar 2026 | $310.3M | 0.15% |
| Dec 2025 | $309.8M | 0.14% |
| 26 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement